Cereton, 400 mg, 28 pcs.

1 capsule contains:

active substance:

choline alfoscerate in terms of 100% substance - 400 mg;

Excipients:

glycerol

purified water;

capsule composition :

gelatin,

sorbitol,

glycerol

methyl parahydroxybenzoate,

propyl parahydroxybenzoate,

titanium dioxide

iron oxide yellow oxide,

purified water.

Pharmacodynamics

Cereton is a nootropic agent. Central cholinostimulator, which contains 40.5% metabolically protected choline. Metabolic protection promotes the release of choline in the brain.

Provides the synthesis of acetylcholine and phosphatidylcholine in neuronal membranes, improves blood flow and enhances metabolic processes in the central nervous system, activates the reticular formation.

Increases the linear velocity of blood flow on the side, traumatic brain damage, helps to normalize the spatio-temporal characteristics: spontaneous bioelectrical activity of the brain, regression of focal neurological symptoms and recovery of consciousness; it has a positive effect on cognitive and behavioral reactions of patients with vascular diseases of the brain (discirculatory encephalopathy and residual effects of cerebrovascular accident).

It has a preventive and corrective effect on pathogenetic factors of involutional psycho-organic syndrome, changes the phospholipid composition of neuron membranes: it participates in the synthesis of phosphatidylcholine (membrane phospholipid), improves the plasticity of neuronal membranes. Stimulates dose-dependent secretion of acetylcholine under physiological conditions, improves synaptic transmission, receptor function. It does not affect the reproductive cycle and does not have a teratogenic, mutagenic effect.

Pharmacokinetics

It easily penetrates the blood-brain barrier, 85% is excreted by the lungs in the form of carbon dioxide, the remaining amount (15%) is excreted by the kidneys and through the intestines.

• the recovery period of severe traumatic brain injury and ischemic stroke, the recovery period of hemorrhagic stroke, occurring with focal hemispheric symptoms or symptoms of damage to the brain stem;
• psycho-organic syndrome against the background of degenerative and involutional changes in the brain;
• cognitive disorders (impaired mental function, memory, confusion, disorientation, decreased motivation, initiative and ability to concentrate), including in dementia and encephalopathy;
• senile pseudomelancholy.

The use of the drug Cereton during pregnancy and during breastfeeding is contraindicated.

At the time of treatment with Cereton, breast-feeding should be discontinued.

• hypersensitivity to the drug;
• acute stage of hemorrhagic stroke;
• pregnancy; period of breastfeeding;
• children under 18 years of age (due to lack of data).

Perhaps the appearance of nausea (mainly as a result of dopaminergic activation), in this case, reduce the dose of the drug.

Allergic reactions.

In the recovery period of traumatic brain injury, ischemic or hemorrhagic stroke, Cereton is prescribed 800 mg in the morning and 400 mg in the afternoon for 6 months.

In chronic cerebrovascular insufficiency and dementia syndromes, Cereton is prescribed 400 mg (1 capsule) 3 times a day, preferably after meals, for 3-6 months.

Nausea may be noted.

Treatment: symptomatic therapy.

Cereton does not affect the speed of psychomotor reactions.

Capsules